Phase II Study of Bortezomib in Combination With Cyclophosphamide and Rituximab for Relapsed/Refractory Mantle Cell Lymphoma
Phase of Trial: Phase II
Latest Information Update: 01 May 2017
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Filgrastim; Mesna; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Sponsors Millennium
- 25 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 16 Sep 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
- 30 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.